GenapSys said that is has raised $90 million in a Series C funding round.
The round was led by Foresite Capital and brings the total funding raised by the firm to date to $166 million.
The Redwood, California-based company plans to use the new funds to drive the commercial launch of its first sequencing instrument, the GenapSys Sequencer, which is now available for order in the US at a list price of $9,995, with a global launched planned for early 2020.
The sequencer uses a stepwise sequencing-by-synthesis chemistry and detects the incorporation of nucleotides through an electrical signal, measured using CMOS-based detectors on a microfluidic chip.
According to the company’s website, the platform routinely generates data where more than 80 percent of bases have a quality score greater than Q30, with an average read length of more than 150 base pairs.
As previously reported, the system can run three types of chips with 1 million, 16 million, and 144 million sensors, respectively. The 16-million chip generates 1.2 Gb to 2 Gb of data, according to the firm, and the 144 million sensor chip will be available next year.